Tech Center 1600 • Art Units: 1638
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17761876 | ENDOTHELIAL AND SMOOTH MUSCLE LIKE TISSUE PRODUCED FROM URINE CELLS AND USES RELATED THERETO | Non-Final OA | EMORY UNIVERSITY |
| 18278771 | EXTRACELLULAR VESICLES DERIVED FROM INDUCED PLURIPOTENT AND EMBRYONIC STEM CELLS, AND METHODS OF USE FOR IMMUNE MODULATION | Non-Final OA | The Regents of the University of California |
| 17911306 | COMPOSITIONS AND METHODS FOR PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS | Non-Final OA | The Regents of the University of California |
| 17775859 | LENTIVIRAL VECTORS IN HEMATOPOIETIC STEM CELLS TO TREAT RECOMBINATION-ACTIVATING GENE 1 (RAG1) SEVERE COMBINED IMMUNODEFICIENCY (SCID) | Final Rejection | The Regents of the University of California |
| 17792203 | CELLS HAVING HIGH ADAPTABILITY UNDER HYPOXIC CONDITIONS, AND USE THEREOF | Non-Final OA | TOOLGEN INCORPORATED |
| 17628517 | ENGINEERED NUCLEIC ACID REGULATORY ELEMENT AND METHODS OF USES THEREOF | Final Rejection | REGENXBIO INC. |
| 17957176 | METHOD OF ENHANCING STRUCTURAL INTEGRITY OF EPIDERMIS IN CULTURE OF RECONSTRUCTED HUMAN SKIN | Final Rejection | Korea University Research and Business Foundation |
| 18261471 | GENERATION OF INDUCED HUMAN THYMIC EPITHELIAL CELLS AND ITS APPLICATION IN CELL-BASED IMMUNOTHERAPIES | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17904075 | ORTHOGONAL SAFETY SWITCHES TO ELIMINATE GENETICALLY ENGINEERED CELLS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17772385 | MEDIUM AND METHODS FOR CULTURING ORGANOIDS | Final Rejection | UNIVERSITY HEALTH NETWORK |
| 17801917 | INDUCIBLE SINGLE AAV SYSTEM AND USES THEREOF | Final Rejection | University of Massachusetts |
| 17906715 | METHOD OF ENGINEERING AND ISOLATING ADENO-ASSOCIATED VIRUS | Non-Final OA | Dignity Health |
| 17762693 | MULTI-TARGETING EFFECTOR CELLS AND USE THEREOF | Final Rejection | Fate Therapeutics, Inc. |
| 18564498 | BIOENGINEERED DERMAL PAPILLA AND HAIR FOLLICLES AND RELATED PRODUCTS, METHODS AND APPLICATIONS | Non-Final OA | The University of Hong Kong |
| 17933730 | METHOD FOR DIFFERENTIATION OF BRAIN MURAL CELLS FROM HUMAN PLURIPOTENT STEM CELLS | Non-Final OA | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 17793287 | INDUCIBLE TISSUE CONSTRUCTS AND USES THEREOF | Non-Final OA | TRUSTEES OF BOSTON UNIVERSITY |
| 17782252 | ADOPTIVE CELL THERAPY WITH ZBTB20 SUPPRESSION | Non-Final OA | THE TRUSTEES OF DARTMOUTH COLLEGE |
| 17779830 | DEVICES, METHODS AND ASSAYS FOR BIOLOGICAL MATERIALS | Final Rejection | StemCell Technologies Canada Inc. |
| 17926145 | METHOD FOR GENERATING FUNCTIONAL SKELETAL MUSCLE FIBERS INNERVATED BY MOTONEURONS | Non-Final OA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE |
| 18542586 | Factor VIII Molecules and Their Use | Non-Final OA | Expression Therapeutics, LLC |
| 17927078 | Lentiviral System | Non-Final OA | Expression Therapeutics, LLC |
| 17346630 | METHODS TO ELIMINATE CANCER STEM CELLS BY TARGETING CD47 | Final Rejection | The U.S.A, as represented by the Secretary, Department of Health and Human Services |
| 18566518 | CELL COMPOSITION, METHOD FOR PRODUCING CELL COMPOSITION, AND PHARMACEUTICAL COMPOSITION CONTAINING CELL COMPOSITION | Non-Final OA | KIRIN HOLDINGS KABUSHIKI KAISHA |
| 18564427 | VIRAL VECTOR PRODUCTION | Non-Final OA | pHion Therapeutics Ltd. |
| 17759183 | COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS | Non-Final OA | SPARK THERAPEUTICS, INC. |
| 18262069 | METHODS FOR OPTIMIZING REPRODUCTIVE TISSUE DERIVED CELL YIELD AND VIABILITY FOR CLINICAL APPLICATIONS | Non-Final OA | GALLANT PET. INC. |
| 18219342 | Bioengineered and standardized Human Tissue Reference Controls for Validation of IHC, FISH or CISH Cancer Test Results | Non-Final OA | SLMP, LLC |
| 18011592 | VECTOR | Non-Final OA | The University of Bristol |
| 18299989 | TREATMENT OF NEUROMUSCULAR DISEASES VIA GENE THERAPY THAT EXPRESSES KLOTHO PROTEIN | Non-Final OA | Fundació Hospital Universitari Vall d’Hebron-Institut de Recerca |
| 18007550 | RNA Replicon for Versatile and Efficient Gene Expression | Non-Final OA | TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenber-Universitä Mainz |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy